Predictive Oncology Inc. (NASDAQ:POAI) Short Interest Down 26.1% in February

Predictive Oncology Inc. (NASDAQ:POAI) was the recipient of a significant decline in short interest in the month of February. As of February 15th, there was short interest totalling 463,100 shares, a decline of 26.1% from the January 31st total of 626,700 shares. Based on an average daily trading volume, of 2,000,000 shares, the short-interest ratio is currently 0.2 days. Approximately 6.5% of the company’s shares are sold short.

Predictive Oncology Stock Performance

Shares of Predictive Oncology stock traded up $0.03 during midday trading on Tuesday, hitting $1.29. The company had a trading volume of 118,035 shares, compared to its average volume of 1,695,753. The stock has a market capitalization of $8.83 million, a P/E ratio of -0.42 and a beta of 1.25. The company has a 50 day moving average of $1.34 and a 200 day moving average of $0.98. Predictive Oncology has a 52-week low of $0.55 and a 52-week high of $3.11.

Analyst Ratings Changes

Separately, HC Wainwright restated a “neutral” rating on shares of Predictive Oncology in a report on Friday, November 15th.

Predictive Oncology Company Profile

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.